上实城开(00563.HK)为上海医药(02607.HK)提供项目管理服务 管理费480万人币
上实城市开发(00563.HK)公布,5月26日在上海医药股份委任之一家竞标代理完成举行招标程序後,公司之全资附属公司上实城开上海建设与上海医药股份(02607.HK)订立项目管理服务协议。
根据项目管理服务协议,上实城开上海建设同意就建设生产基地项目工程,向上海医药股份提供项目管理服务,管理费总额为480万元人民币。
於公告日期,上海医药股份为上实集团(即公司控股股东)之附属公司。因此上海医药股份为上实集团之联系人及公司之关连人士。(el/u) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.